» Articles » PMID: 32473687

Guideline No. 398: Progesterone for Prevention of Spontaneous Preterm Birth

Overview
Publisher Elsevier
Date 2020 Jun 1
PMID 32473687
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes.

Options: To administer or withhold progesterone therapy for women deemed to be at high risk of SPB.

Outcomes: Preterm birth, neonatal morbidity and mortality, and postnatal outcomes including neurodevelopmental outcomes.

Intended Users: Maternity care providers, including midwives, family physicians, and obstetricians.

Target Population: Pregnant women at increased risk of SPB.

Evidence: Medline, PubMed, EMBASE, and the Cochrane Library were searched from inception to October 2018 for medical subject heading (MeSH) terms and keywords related to pregnancy, preterm birth, previous preterm birth, short cervix, uterine anomalies, cervical conization, neonatal morbidity and mortality, and postnatal outcomes. This document represents an abstraction of the evidence rather than a methodological review.

Validation Methods: This guideline was reviewed by the Maternal-Fetal Medicine Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and approved by the SOGC Board of Directors.

Benefits, Harms, And/or Costs: Therapy with progesterone significantly reduces the risk of SPB in a subpopulation of women at increased risk. Although this therapy entails a cost to the woman in addition to the discomfort associated with its use, no other adverse effects to the mother or the baby have been identified.

Summary Statements (grade Ratings In Parentheses): RECOMMENDATIONS (GRADE RATINGS IN PARENTHESES).

Citing Articles

Different interventions to prevent preterm birth in pregnant women with cervical shortening during pregnancy: a protocol for a network meta-analysis.

Luo J, Liu D, Liu J BMJ Open. 2024; 14(11):e084015.

PMID: 39532349 PMC: 11574485. DOI: 10.1136/bmjopen-2024-084015.


Maternal Infection and Preterm Birth: From Molecular Basis to Clinical Implications.

Daskalakis G, Psarris A, Koutras A, Fasoulakis Z, Prokopakis I, Varthaliti A Children (Basel). 2023; 10(5).

PMID: 37238455 PMC: 10217143. DOI: 10.3390/children10050907.


Effect of Neurosteroids on Basal and Stress-Induced Oxytocin Secretion in Luteal-Phase and Pregnant Sheep.

Mlotkowska P, Marciniak E, Misztal A, Misztal T Animals (Basel). 2023; 13(10).

PMID: 37238088 PMC: 10215827. DOI: 10.3390/ani13101658.


Maternal Plasma RNA in First Trimester Nullipara for the Prediction of Spontaneous Preterm Birth ≤ 32 Weeks: Validation Study.

Weiner C, Zhou H, Cuckle H, Syngelaki A, Nicolaides K, Weiss M Biomedicines. 2023; 11(4).

PMID: 37189767 PMC: 10135717. DOI: 10.3390/biomedicines11041149.


Evaluation of a Maternal Plasma RNA Panel Predicting Spontaneous Preterm Birth and Its Expansion to the Prediction of Preeclampsia.

Weiner C, Cuckle H, Weiss M, Buhimschi I, Dong Y, Zhou H Diagnostics (Basel). 2022; 12(6).

PMID: 35741140 PMC: 9221694. DOI: 10.3390/diagnostics12061327.